Komentář ke článku HOPE-3: Statins Lower CV Events in Intermediate-CHD-Risk Patients

Overview

The HOPE-3 study focused on identifying the significance of the polypill and mini-polypill in broad clinical practice, including individuals of different gender without cardiovascular diseases with an intermediate risk of cardiovascular diseases. The authors were interested in the question whether people from various antropologhy groups including not only white people but also other antropologhy groups – the blacks, people of Asian and South American origin and more covering 6 continents, would respond in a similar way. The study mainly examined the significance of the mini-polypill, comprising the use of antihypertensive treatment (16 mg candesartan per day + 12.5 mg hydrochlorothiazide), treatment with statins (10 mg rosuvastatin per day), and their combination. The study presents a new way forward in the prevention of cardiovascular diseases, but it also entails some weaknesses which consist in rather rare medical checkups including laboratory tests. Owing to that the concept of mini-polypill has met with some reservation. But it also brings with it reduction of healthcare costs.

Key words:
mini-polypill – prevention of cardiovascular diseases – relevance of statins also to primary prevention